April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
New handheld, non-mydriatic ERG device to screen for diabetic retinopathy and other eye diseases
Author Affiliations & Notes
  • Byongdo Kim
    University of California, Berkeley, Berkeley, CA
  • Evelyn Ross
    University of Iowa College of Public Health, Iowa City, CA
  • Kimberly Pham
    University of California, Berkeley, Berkeley, CA
  • Jenny Nguyen
    University of Southern California, Los Angeles, CA
  • Vinna Nam
    University of California, Berkeley, Berkeley, CA
  • Vidhya Gunasekaran
    Ophthalmology, Aravind Eye Hospital, Madurai, India
  • Scott E Brodie
    Ophthalmology, Mount Sinai School of Medicine, New York City, NY
  • Gloria Wu
    Ophthalmology, Stanford Hospital & Clinics, Stanford, CA
  • Footnotes
    Commercial Relationships Byongdo Kim, None; Evelyn Ross, None; Kimberly Pham, None; Jenny Nguyen, None; Vinna Nam, None; Vidhya Gunasekaran, None; Scott Brodie, None; Gloria Wu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5118. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Byongdo Kim, Evelyn Ross, Kimberly Pham, Jenny Nguyen, Vinna Nam, Vidhya Gunasekaran, Scott E Brodie, Gloria Wu, ; New handheld, non-mydriatic ERG device to screen for diabetic retinopathy and other eye diseases. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5118.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the use of the 30 Hz RETeval(TM) handheld ERG device in diabetic and glaucoma patients in the office setting.

 
Methods
 

The RETeval(TM) (LKC Gaithersburg, MD) is a small handheld ERG device using adhesive skin electrodes in lieu of contact lens electrodes to assess cone function in patients without mydriasis. The RETeval(TM) is currently in Phase 2 and 3 clinical trials (US FDA, and EC, respectively). RETeval(TM) (REv) was used in patients with diabetes mellitus and glaucoma patients in a retina practice in San Jose, CA. Inclusion criteria: Diabetic pts HbA1c > 6.0 mg/dL or FBS > 100 mg/dL; Glaucoma patients were verified by visual field findings. Visual acuity was 20/15-20/40. The Stata statistical software program was used. For each patient, ERG data from only one eye was used, based on randomization by coin toss. Informed consent was obtained.

 
Results
 

A total of 50 patients and controls were enrolled over 3 months: Control (C): n=22: age range 23-75 yrs, avg=47.9, sd=16.3; Diab (DM): n=12: age range 23-77 yrs, avg=55.8,sd=14.6; Glaucoma (G) n=17: age range=37-76 yrs, avg=59.2, sd=11.95. ERG photopic implicit times were prolonged in both diabetic and glaucoma patients: 2 tailed t-test: Control mean 33.2 msec vs DM mean 34.6 msec, implicit time p=0.045; Control mean 33.2 msec vs G mean 35.4 msec, implicit time p=0.0009. No significant differences were noted between implicit times in the diabetic and glaucomatous patients or for difference in response in amplitude: C vs DM: p=0.26.

 
Conclusions
 

This small study suggests that prolongation of flicker implicit times in diabetes and glaucoma can be discerned with the RETeval(TM) in a clinical setting. The RETeval(TM) may thus be of value as a screening tool in nursing homes or facilities where ophthalmic exams are not available.

     
Keywords: 498 diabetes • 509 electroretinography: clinical • 465 clinical (human) or epidemiologic studies: systems/equipment/techniques  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×